Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Patrik Weder"'
Autor:
Sabine Schmid, Dirk Klingbiel, Stefan Aebi, Aron Goldhirsch, Christoph Mamot, Elisabetta Munzone, Franco Nolè, Christian Oehlschlegel, Olivia Pagani, Bernhard Pestalozzi, Christoph Rochlitz, Beat Thürlimann, Roger von Moos, Patrik Weder, Khalil Zaman, Thomas Ruhstaller
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background The impact of HER2-targeted therapy alone followed by the addition of chemotherapy at disease progression (PD) versus upfront combination was investigated by the SAKK 22/99 trial. The aim of this exploratory analysis of the SAKK 2
Externí odkaz:
https://doaj.org/article/3a71b23e5f6e4fdeb49b83bd63c454c7
Autor:
Martin Zweifel, Beat Thürlimann, Salome Riniker, Patrik Weder, Roger von Moos, Olivia Pagani, Martin Bigler, Karin M Rothgiesser, Christiane Pilop, Hanne Hawle, Peter Brauchli, Coya Tapia, Wolfgang Schoenfeld, Cristiana Sessa
Publikováno v:
Endocrine Connections, Vol 6, Iss 7, Pp 549-556 (2017)
CR1447 (4-hydroxytestosterone, 4-OHT) binds to the androgen receptor and has antiproliferative activity in both ER-positive and ER-negative/AR-positive breast cancer cells in preclinical studies. The objective of this first-in man trial was to evalua
Externí odkaz:
https://doaj.org/article/c9dddec557f8412bb8c5901ee09bbf31
Autor:
Caroline J Voskens, Simone M Goldinger, Carmen Loquai, Caroline Robert, Katharina C Kaehler, Carola Berking, Tanja Bergmann, Clemens L Bockmeyer, Thomas Eigentler, Michael Fluck, Claus Garbe, Ralf Gutzmer, Stephan Grabbe, Axel Hauschild, Rüdiger Hein, Gheorghe Hundorfean, Armin Justich, Ullrich Keller, Christina Klein, Christine Mateus, Peter Mohr, Sylvie Paetzold, Imke Satzger, Dirk Schadendorf, Marc Schlaeppi, Gerold Schuler, Beatrice Schuler-Thurner, Uwe Trefzer, Jens Ulrich, Julia Vaubel, Roger von Moos, Patrik Weder, Tabea Wilhelm, Daniela Göppner, Reinhard Dummer, Lucie M Heinzerling
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e53745 (2013)
Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients. Treatment algorithms for the management of common ipilimum
Externí odkaz:
https://doaj.org/article/1e9dff99dd604582ac2c2c7a3f9fad75
Autor:
Bernhard C. Pestalozzi, Patrik Weder, Dirk Klingbiel, Stefan Aebi, Sabine Schmid, Christoph Mamot, Franco Nolè, Christoph Rochlitz, Roger von Moos, Elisabetta Munzone, Thomas Ruhstaller, Christian Oehlschlegel, Olivia Pagani, Aron Goldhirsch, Khalil Zaman, Beat Thürlimann
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)
BMC Cancer
BMC cancer, vol. 19, no. 1, pp. 902
BMC Cancer
BMC cancer, vol. 19, no. 1, pp. 902
Background The impact of HER2-targeted therapy alone followed by the addition of chemotherapy at disease progression (PD) versus upfront combination was investigated by the SAKK 22/99 trial. The aim of this exploratory analysis of the SAKK 22/99 tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0fad97b26e69b7b3985c7909d4190ca
http://link.springer.com/article/10.1186/s12885-019-6105-3
http://link.springer.com/article/10.1186/s12885-019-6105-3
Autor:
Thomas Ruhstaller, Patrik Weder
Publikováno v:
Forum Médical Suisse ‒ Swiss Medical Forum.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::119ac6c1329d7daa4aa83819898e1798
https://doi.org/10.4414/fms.2020.08475
https://doi.org/10.4414/fms.2020.08475
Autor:
B. Thuerlimann, Christiane Pilop, Karin Rothgiesser, Peter Brauchli, Coya Tapia, Martin Zweifel, S. Riniker, W Schoenfeld, Patrik Weder, Martin Bigler, Cristiana Sessa, R. von Moos, Olivia Pagani
Publikováno v:
Cancer Research. 76:P5-14
Background: CR1447 (4-OH-testosterone, 4-OHT), a steroidal small molecule, strongly binds to the androgen receptor (AR) and has aromatase inhibiting activity. Pre-clinical studies show that CR1447 given as an ointment is efficiently absorbed and has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c76b524b03d98d7ffca8cf22986d0d3c
https://doi.org/10.1158/1538-7445.sabcs15-p5-14-05
https://doi.org/10.1158/1538-7445.sabcs15-p5-14-05
Autor:
Laurence Vanlemmens, Beat Thürlimann, Jens Huober, Karin Ribi, Hervé Bonnefoi, Epie Boven, Qiyu Li, Jérôme Lemonnier, Patrik Weder, M.-A. Gerard
Publikováno v:
Annals of Oncology. 30:iii47
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bcce52523fdc39dae9175210b934395
https://doi.org/10.1093/annonc/mdz100.001
https://doi.org/10.1093/annonc/mdz100.001
Autor:
Detlef Brügge, Paul Martin Putora, Johannes Weber, Patrik Weder, Thomas Hundsberger, Ludwig Plasswilm
Publikováno v:
Journal of Neuro-Oncology. 112:133-139
The optimal treatment for recurrent high-grade gliomas is unknown and a standard of care does not exist. Re-irradiation with concomitant bevacizumab represents an option. Retrospectively, we analyzed a cohort of heavily pretreated patients (n = 14) w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::763b74ad396ec108af6f24df05e7669b
https://doi.org/10.1007/s11060-013-1044-3
https://doi.org/10.1007/s11060-013-1044-3
Autor:
Beat Thürlimann, Hervé Bonnefoi, Laurence Vanlemmens, Jérôme Lemonnier, Jens Huober, Christine Levy, V. Membrez-Antonioli, Séverine Guiu, Patrik Weder, A.M. Savoye, A. Xyrafas, Epie Boven, J. Grenier, Etienne Brain, A. Müller, Corinne Veyret, Hanne Hawle, Florence Dalenc, M.-A. Gerard
Publikováno v:
Annals of Oncology. 29:viii93
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::250e72012091154e85172ce2d150751c
https://doi.org/10.1093/annonc/mdy272.280
https://doi.org/10.1093/annonc/mdy272.280
Autor:
Lucie Heinzerling, Jens Ulrich, Caroline Robert, Ullrich Keller, Sylvie Paetzold, Imke Satzger, Marc Schlaeppi, Carmen Loquai, Katharina C. Kaehler, Armin Justich, Carola Berking, Stephan Grabbe, Peter Mohr, Gerold Schuler, Christina Klein, Uwe Trefzer, Dirk Schadendorf, Gheorghe Hundorfean, Daniela Göppner, Julia Vaubel, Ralf Gutzmer, Claus Garbe, Clemens L. Bockmeyer, Tabea Wilhelm, Tanja Bergmann, Caroline J. Voskens, Patrik Weder, Beatrice Schuler-Thurner, Rüdiger Hein, Axel Hauschild, Christine Mateus, Michael Fluck, Reinhard Dummer, Roger von Moos, Simone M. Goldinger, Thomas Eigentler
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e53745 (2013)
PLoS ONE
PLoS ONE
Background: Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients. Treatment algorithms for the management of com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51fdaa9f9e19387f59e15ceacb0c39f4
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=84872339660
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=84872339660
